Skip to main content

Advertisement

SpringerLink
Log in

Liposomal formulations for lung cancer treatment in the last two decades: a systematic review

  • Review – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Lung cancer is the leading cause of cancer mortality worldwide. To improve the therapeutic outcomes, drug delivery systems, and particularly liposomes, have been widely investigated. Therefore, this review analyzed systematically the literature to inquire about the safety and efficacy of liposomal formulations in lung cancer treatment.

Methods

Three electronic databases (PubMed, Web of Science and Cochrane CENTRAL) were systematically searched until May 2020. Clinical trials containing information about the effects of liposomal formulations in lung cancer patients were considered eligible.

Results

Twenty two selected studies present different treatment options for both small and non-small-cell lung cancers. After compiling and analyzing all the published information, we verified that combination of liposomal cisplatin and paclitaxel led to a statistically significant improvement of the evaluated outcomes. Moreover, tecemotide, a liposome-based immunotherapy, demonstrated lower toxicity compared to control groups. Evidences that other subgroups could benefit from this formulation were also provided.

Conclusion

This systematic review (registration number CRD42021246587) demonstrates that liposomal formulations are promising alternatives to overcome limitations of traditional cancer therapy. However, larger, longer, randomized and double-blinded clinical trials, selecting their patients’ cohort considering more responsive subgroups would be beneficial to strengthen the scientific and clinical evidence of the results herein reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Boulikas T (2009) Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18:1197–1218

    Article  CAS  Google Scholar 

  • Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9:12

    Article  Google Scholar 

  • Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E et al (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137:1337–1342

    Article  CAS  Google Scholar 

  • Butts C, Murray N, Maksymiuk A, Goss G, Marshall E et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674–6681

    Article  CAS  Google Scholar 

  • Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K et al (2010) A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 11:391–395

    Article  CAS  Google Scholar 

  • Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L et al (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:59–68

    Article  CAS  Google Scholar 

  • CASP (2018) Critical appraisal skills programme: randomised controlled trial 2018

  • Chen G, Sheng L, Du X (2018) Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 82:505–510

    Article  CAS  Google Scholar 

  • Giodini L, Re FL, Campagnol D, Marangon E, Posocco B et al (2017) Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine 13:583–599

    Article  CAS  Google Scholar 

  • Institute NC (2020) Common terminology criteria for adverse events v6.0 (CTCAE)

  • Katakami N, Hida T, Nokihara H, Imamura F, Sakai H et al (2017) Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer 105:23–30

    Article  Google Scholar 

  • Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J (2013) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2013:Cd006910

    PubMed Central  Google Scholar 

  • Leighl NB, Burkes RL, Dancey JE, Lopez PG, Higgins BP et al (2003) A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. Clin Lung Cancer 5:107–112

    Article  CAS  Google Scholar 

  • Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE et al (2006) Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer 52:327–332

    Article  Google Scholar 

  • Lu B, Sun L, Yan X, Ai Z, Xu J (2015) Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Med Oncol 32:345

    Article  Google Scholar 

  • Lv WZ, Lin Z, Wang SY, Lv BJ, Wang ZH et al (2019) Phase II study of a Bi-weekly chemotherapy regimen of combined liposomal paclitaxel and nedaplatin for the treatment of advanced squamous cell lung cancer. Transl Oncol 12:656–660

    Article  Google Scholar 

  • Menon JU, Kuriakose A, Iyer R, Hernandez E, Gandee L et al (2017) Dual-drug containing core-shell nanoparticles for lung cancer therapy. Sci Rep 7:13249

    Article  Google Scholar 

  • Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K et al (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 26:1134–1142

    Article  CAS  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535

    Article  Google Scholar 

  • Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A et al (2010) Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 68:240–247

    Article  CAS  Google Scholar 

  • Novello S, Barlesi F, Califano R, Cufer T, Ekman S et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 27:v1–v27

    Article  CAS  Google Scholar 

  • Numico G, Castiglione F, Granetto C, Garrone O, Mariani G et al (2002) Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35:59–64

    Article  Google Scholar 

  • Palmer M, Parker J, Modi S, Butts C, Smylie M et al (2001) Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3:49–57 (Discussion 58)

    Article  CAS  Google Scholar 

  • Patlakas G, Bouros D, Tsantekidou-Pozova S, Koukourakis MI (2005) Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res 25:1427–1431

    CAS  PubMed  Google Scholar 

  • Ravaioli A, Papi M, Pasquini E, Marangolo M, Rudnas B et al (2009) Lipoplatin monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J Chemother 21:86–90

    Article  CAS  Google Scholar 

  • Sharma B, Crist RM, Adiseshaiah PP (2017) Nanotechnology as a delivery tool for precision cancer therapies. AAPS J 19:1632–1642

    Article  CAS  Google Scholar 

  • Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716

    Article  Google Scholar 

  • Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A et al (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 21:2227–2232

    Article  CAS  Google Scholar 

  • Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K et al (2011) Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 68:945–950

    Article  CAS  Google Scholar 

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

    Article  Google Scholar 

  • Villaruz LC, Socinski MA (2013) The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 19:2629–2636

    Article  Google Scholar 

  • Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA et al (2000) A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer 2:128–132

    Article  CAS  Google Scholar 

  • Wang X, Zhou J, Wang Y, Zhu Z, Lu Y et al (2010) A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 46:1474–1480

    Article  CAS  Google Scholar 

  • Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268

    Article  CAS  Google Scholar 

  • White SC, Lorigan P, Margison GP, Margison JM, Martin F et al (2006) Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 95:822–828

    Article  CAS  Google Scholar 

  • Woodman C, Vundu G, George A, Wilson CM (2021) Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol 69:349–364

    Article  CAS  Google Scholar 

  • Wurz GT, Kao C-J, Wolf M, DeGregorio MW (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 10:3383–3393

    Article  Google Scholar 

  • Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E et al (2011) Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol 68:63–68

    Article  CAS  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal

    Filipa Canão

  2. 3B’s Research Group, I3Bs Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, 4805-017, Barco/Guimarães, Portugal

    Helena Ferreira & Nuno M. Neves

  3. ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal

    Helena Ferreira & Nuno M. Neves

Authors
  1. Filipa Canão
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helena Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nuno M. Neves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Helena Ferreira or Nuno M. Neves.

Ethics declarations

Conflict of interest

Authors have no conflicts of interest.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 88 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Canão, F., Ferreira, H. & Neves, N.M. Liposomal formulations for lung cancer treatment in the last two decades: a systematic review. J Cancer Res Clin Oncol 148, 2375–2386 (2022). https://doi.org/10.1007/s00432-022-04079-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-022-04079-x

Keywords

Search

Navigation